ALİ OGUL, SEMRA PAYDAS, ABDULLAH EVREN YETİSİR, CEM MİRİLİ, MAHMUT BÜYÜKSİMSEK
Eurasian Journal of Medical Investigation - 2020;4(4):428-432
Objectives: The aim of this study is to determine the biomarkers in LON (Late Onset Neutropenia) associated with rituximab using in lymphoproliferative diseases (LPDs). Methods: : In this retrospective study 22 cases with LPD treated by rituximab containing regimen and followed at least one year in our center were evaluated for LON. Results: Grade I, II and IV neutropenia were detected in five, five and one cases, respectively. Lowest neutrophil/lymphocyte ratio (NLR) was 1.2 and 1.7 in cases with and without LON, respectively. Neutropenia developed in 8 of 15 cases with Diffuse large B cell lymphoma (DLBCL), 2 of 2 cases with Follicular Lymphoma (FL) and one case of Small lymphocytic lymphoma (SLL). According to prophylactic Granulocyte colony-stimulating factor (G-CSF) using, neutropenia was detected in all cases given prophylaxis while 6 of 17 cases without prophylaxis. Mean rituximab dose was 4870 mg in cases developing neutropenia while it was 4162 mg in cases without neutropenia. Conclusion: Lower NLR at the end of treatment cycle, G-CSF using with prophylaxis aim, extranodal involvement and more than 4 gr rituximab using were found as the predictive factors for LON associated with rituximab.
